Metformin for asthma control in children who are overweight or obese
Tests metformin against a placebo in overweight or obese children with asthma.
Plain-language title generated from the registry record
Registry title: Metformin Treatment for Children With Obesity-associated Asthma
Key facts
- Where
- Doha, QatarSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 17 years old?
Source: NCT07622290, who can take part
Where in Qatar
- Sidra MedicineDoha, QatarNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prof Ibrahim Janahi
- Trial code
- NCT07622290
- Record updated
- 3 June 2026
- Original description
The goal of this clinical trial is to learn if metformin can improve asthma control in overweight and obese children with mild, moderate, or severe asthma. It will also evaluate the safety and metabolic effects of metformin in this population. The main questions the study aims to answer are:Read full original descriptionShow less
The Role of Metformin in Asthma Control in Obese/Overweight Children, a Randomized Placebo Controlled Clinical Trial
The goal of this clinical trial is to learn if metformin can improve asthma control in overweight and obese children with mild, moderate, or severe asthma. It will also evaluate the safety and metabolic effects of metformin in this population. The main questions the study aims to answer are:
1) Does metformin improve asthma control, as measured by the Asthma Control Test (ACT) score? 2) Does metformin improve lung function, reduce asthma exacerbations, and improve metabolic and inflammatory markers in overweight/obese children with asthma? Researchers will compare metformin with a placebo (a look-alike substance that contains no active drug) to see if metformin improves asthma outcomes in overweight/obese children with asthma. Participants will take either metformin or a placebo in addition to their standard asthma treatment during the study period. They will attend scheduled clinic visits for asthma assessments, lung function testing, and safety monitoring. Blood, stool, and saliva samples, along with clinical information, will be collected from participants to assess asthma control, and markers related to metabolism and inflammation. Participants will also complete asthma control questionnaires and report medication use and asthma symptoms throughout the study period.
Inclusion: Participant who are capable of giving assent and parentral consent; Male/Female participant aged between10-17 years old,; overweight/obese children (Overweight and obesity are defined as BMI equal and above the 85th percentile, and BMI above the 95th percentile for age and sex, respectively); Diagnosed with mild persistent, moderate persistent /severe asthma based on GINA guidelines within the 6 months prior to the recruitment date and having ACT score < 20, residing in Qatar; Partcipants on standard asthma therapy for at least the last 6 months prior to the recruitment; Participant who are currently not taking part in any other interventional study.
Exclusion: Symptomatic or previously symptomatic congenital heart disease; Taking metformin or GLP1 medication less than 3 months of the recruitment date; Non-asthma chronic lung disease; Inflammatory bowel disease; Syndromic disorders (e.g. Down's syndrome, Turner's syndrome); Neuromuscular disorders; Swallowing disorders; Ongoing treatment for cancer; Children diagnosed with type-1 diabetes; Broncho-pulmonary dysplasia; Inborn errors of metabolism; Craniofacial abnormalities; Primary thoracic cage abnormalities; Secondary endocrinopathies causing obesity; Renal complications.